BioMarin Pharmaceutical IncNASDAQ:BMRN
- LAST PRICE64.8100
- TODAY'S CHANGE (%)-0.2800 (-0.4302%)
- Bid / Lots64.8200/ 1
- Ask / Lots64.8500/ 2
- Open / Previous Close65.0000 / 65.0900
- Day Range
- 52 Week Range
- Volume429,837
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BMRN |
|---|---|---|
| 09:32 ET | 10843 | 64.8 |
| 09:33 ET | 1538 | 65.06 |
| 09:35 ET | 819 | 64.865 |
| 09:37 ET | 200 | 64.865 |
| 09:39 ET | 400 | 64.67 |
| 09:42 ET | 5197 | 64.6 |
| 09:44 ET | 821 | 64.67 |
| 09:46 ET | 1841 | 64.505 |
| 09:48 ET | 1168 | 64.525 |
| 09:50 ET | 3237 | 64.51 |
| 09:51 ET | 4114 | 64.51 |
| 09:53 ET | 4907 | 64.54 |
| 09:55 ET | 4154 | 64.75 |
| 09:57 ET | 2548 | 64.605 |
| 10:00 ET | 500 | 64.6899 |
| 10:02 ET | 100 | 64.66 |
| 10:04 ET | 3449 | 64.67 |
| 10:06 ET | 400 | 64.695 |
| 10:08 ET | 1606 | 64.59 |
| 10:09 ET | 1998 | 64.65 |
| 10:11 ET | 3452 | 64.5006 |
| 10:13 ET | 2803 | 64.515 |
| 10:15 ET | 2759 | 64.6 |
| 10:18 ET | 3394 | 64.66 |
| 10:20 ET | 1661 | 64.645 |
| 10:22 ET | 818 | 64.565 |
| 10:24 ET | 1500 | 64.52 |
| 10:26 ET | 701 | 64.5 |
| 10:27 ET | 1600 | 64.63 |
| 10:29 ET | 1799 | 64.48 |
| 10:31 ET | 342 | 64.45 |
| 10:33 ET | 5889 | 64.507693 |
| 10:36 ET | 3346 | 64.46 |
| 10:38 ET | 5800 | 64.405 |
| 10:40 ET | 900 | 64.4 |
| 10:42 ET | 600 | 64.27 |
| 10:44 ET | 1835 | 64.275 |
| 10:45 ET | 1596 | 64.19 |
| 10:47 ET | 4321 | 64.215 |
| 10:49 ET | 3531 | 64.185 |
| 10:51 ET | 3231 | 64.14 |
| 10:54 ET | 400 | 64.135 |
| 10:56 ET | 237 | 64.14 |
| 10:58 ET | 200 | 64.18 |
| 11:00 ET | 1200 | 64.24 |
| 11:02 ET | 819 | 64.25 |
| 11:03 ET | 1388 | 64.285 |
| 11:05 ET | 2578 | 64.31 |
| 11:07 ET | 100 | 64.29 |
| 11:09 ET | 379 | 64.275 |
| 11:12 ET | 600 | 64.17 |
| 11:14 ET | 337 | 64.13 |
| 11:16 ET | 310 | 64.145 |
| 11:18 ET | 900 | 64.18 |
| 11:20 ET | 1597 | 64.208785 |
| 11:21 ET | 5385 | 64.38 |
| 11:23 ET | 3758 | 64.365 |
| 11:25 ET | 1610 | 64.37 |
| 11:27 ET | 25569 | 64.39 |
| 11:30 ET | 4067 | 64.45 |
| 11:32 ET | 1968 | 64.49 |
| 11:34 ET | 2215 | 64.47 |
| 11:36 ET | 1270 | 64.495 |
| 11:38 ET | 8093 | 64.455 |
| 11:39 ET | 5870 | 64.545 |
| 11:41 ET | 2087 | 64.5 |
| 11:43 ET | 3293 | 64.46 |
| 11:45 ET | 4087 | 64.5 |
| 11:48 ET | 976 | 64.48 |
| 11:50 ET | 1473 | 64.49 |
| 11:52 ET | 312 | 64.49 |
| 11:54 ET | 844 | 64.465 |
| 11:56 ET | 8136 | 64.5 |
| 11:57 ET | 600 | 64.47 |
| 11:59 ET | 8778 | 64.54 |
| 12:01 ET | 480 | 64.53 |
| 12:03 ET | 1610 | 64.53 |
| 12:06 ET | 359 | 64.5009 |
| 12:08 ET | 1600 | 64.55 |
| 12:10 ET | 1222 | 64.57 |
| 12:12 ET | 722 | 64.58 |
| 12:14 ET | 3701 | 64.625 |
| 12:15 ET | 1117 | 64.7095 |
| 12:17 ET | 2243 | 64.665 |
| 12:19 ET | 900 | 64.725 |
| 12:21 ET | 2250 | 64.765 |
| 12:24 ET | 100 | 64.76 |
| 12:26 ET | 655 | 64.72 |
| 12:28 ET | 2932 | 64.66 |
| 12:30 ET | 1356 | 64.68 |
| 12:32 ET | 1108 | 64.73 |
| 12:33 ET | 1000 | 64.76 |
| 12:35 ET | 200 | 64.72 |
| 12:37 ET | 200 | 64.725 |
| 12:39 ET | 3558 | 64.7 |
| 12:42 ET | 2200 | 64.7 |
| 12:44 ET | 1937 | 64.7836 |
| 12:46 ET | 2250 | 64.815 |
| 12:48 ET | 1667 | 64.81 |
| 12:50 ET | 4981 | 64.86 |
| 12:51 ET | 3716 | 64.897 |
| 12:53 ET | 905 | 64.92 |
| 12:55 ET | 1316 | 64.96 |
| 12:57 ET | 922 | 64.96 |
| 01:00 ET | 6336 | 64.89 |
| 01:02 ET | 2068 | 64.8183 |
| 01:04 ET | 1100 | 64.78 |
| 01:06 ET | 100 | 64.805 |
| 01:08 ET | 1697 | 64.83 |
| 01:09 ET | 2778 | 64.89 |
| 01:11 ET | 1336 | 64.8939 |
| 01:13 ET | 301 | 64.912 |
| 01:15 ET | 764 | 64.9 |
| 01:18 ET | 1100 | 64.975 |
| 01:20 ET | 2100 | 64.96 |
| 01:22 ET | 3666 | 64.94 |
| 01:24 ET | 400 | 64.91 |
| 01:26 ET | 1824 | 64.81 |
| 01:27 ET | 1992 | 64.83 |
| 01:29 ET | 1357 | 64.8 |
| 01:31 ET | 1805 | 64.81 |
| 01:33 ET | 100 | 64.815 |
| 01:36 ET | 3450 | 64.82 |
| 01:38 ET | 3273 | 64.81 |
Nov 16, 2024
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO(R) (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024, from 10:45AM ET on Saturday Nov 16, 2024 by Dow Jones
10:45AM ET on Saturday Nov 16, 2024 by Dow Jones
Nov 15, 2024
DJ BioMarin Pharmaceutical Initiated at Outperform by Wolfe Research, from 5:26AM ET on Friday Nov 15, 2024 by Dow Jones
5:26AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 6, 2024
BioMarin to Participate in Three Upcoming Investor Conferences, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
Oct 30, 2024
DJ BioMarin Pharmaceutical Is Maintained at Neutral by Citigroup, from 2:44PM ET on Wednesday Oct 30, 2024 by Dow Jones
2:44PM ET on Wednesday Oct 30, 2024 by Dow JonesDJ BioMarin Pharmaceutical Is Maintained at Hold by Canaccord Genuity, from 1:36PM ET on Wednesday Oct 30, 2024 by Dow Jones
1:36PM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioMarin Pharmaceutical Inc | 12.2B | 39.0x | --- |
Exact Sciences Corp | 9.8B | -51.4x | --- |
Neurocrine Biosciences Inc | 12.7B | 34.1x | +62.04% |
Medpace Holdings Inc | 10.5B | 29.0x | +35.10% |
United Therapeutics Corp | 16.6B | 16.4x | +8.22% |
Qiagen NV | 9.5B | 105.8x | +12.66% |
Company Information
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Contact Information
- Headquarters
- 105 Digital DriveNOVATO, CA, United States 94949
- Phone
- 415-505-6700
- Fax
- 415-382-7889
Executives
- Non-Executive Independent Chairman of the Board
- Richard Meier
- President, Chief Executive Officer, Director
- Alexander Hardy
- Chief Financial Officer, Executive Vice President - Finance
- Brian Mueller
- President - Worldwide Research and Development
- Henry Fuchs
- Executive Vice President - Global Manufacturing and Technical Operations, Chief Technical Officer
- C. Greg Guyer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $12.2B |
|---|---|
Revenue (TTM) | $2.8B |
Shares Outstanding | 190.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.29 |
EPS | $1.66 |
Book Value | $26.25 |
P/E Ratio | 39.0x |
Price/Sales (TTM) | 4.4 |
Price/Cash Flow (TTM) | 29.0x |
Operating Margin | 11.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
